Ontario becomes the first province to list fluvoxamine as a COVID-19 treatment to consider
Fluvoxamine has been proven to work in every trial that has published results, including outpatient and inpatient studies. However, no journal will accept these studies for publication despite successful phase III trials. See Steve Kirsch’s article concerning his attempts to get this information published and for doctors to learn about its success.
Ontario has become the first province to list an inexpensive and well-known antidepressant as a treatment doctors can “consider” for patients with a mild COVID-19 infection in a bid to keep them out of hospital.
In the science table listing on Wednesday, a panel indicated that the drug fluvoxamine can be considered and prescribed to patients with a mild case who are at risk of having more severe symptoms.